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Summary.-The concentration of bound sialic acid in the sera of 56 normal sub-
jects and 65 subjects with breast cancer was measured, in order to determine (1)
whether serum sialic acid concentrations are raised in breast cancer and (2)
whether the concentration of sialic acid in serum reflects tumour stage. The amount
of sialic acid in serum was compared to serum carcinoembryonic antigen (CEA)
values.
Urinary hydroxyproline and serum alkaline phosphatase concentrations were used
as indicators of bone and liver involvement. Erythrocyte sedimentation rate (ESR)
was also measured.
Significantly elevated serum sialic acid concentrations were found in breast
cancer, and showed correlation with tumour stage. Serum sialic acid values did not
correlate with CEA values. The results suggest that measurement of serum sialic
acid concentrations may be of adjunctive value in assessing tumour stage.
_1 SIALIC ACID CONCENTRATIONS of the
ttimour-cell surface were shown to be
related tomalignantpotential andchanges
in immunogenicity (Simmons & Rios,
1974; Simmons et al., 1971 ; Reed et al.,
1974). The changes shown to occur in the
metabolism of tumour-cell sialoglvcopro-
teins (Warren etal., 1972) haveencouraged
the studv of these factors in blood.
Increased bound sialic acid values
have previously been reported in the
sera of patients with cancer in genetp.1
(Macbeth & Bekesi, 1962; Watkins et al.,
1.974; Bradley et al., 1977), of patients
with melanoma (Silver et al., 1978) and of
4 patients with metastatic breast cancer
(Macbeth & Bekesi, 1962).
This paper describes the relationship of
serum sialic acid to tumour stage and
to serum CEA values in breast cancer.
METHODS AND MATERIALS
Fifty-sixhealthy adults who -,vere free from
respiratory infections at the time ofsampling
served as a control group. Sixty-five breast-
cancer patients (age range 45-65 years)
whose tumours had been removed for at least
a month by different surgeons and -%.,ho
received no treatment within 2 weeks of
sampling were studied. They were classified
according to TNM (pathological) and divided
into 4 stages based on the U.I.C.C. 1979
system, with the following modification.
Stages 11 and III are subdivided into "a"
and "b" depending on the presence or absence
ofregionallymph-node involvement. Patients
1ATith Stage 11 disease -,Nho had uninvolved
regional lymph nodes (T2NoMo) are in
Stage Ila, those with involved (NI) nodes are
in Stage Ilb. Patients with Stage III disease
who had uninvolved regional lymph nodes
are in Stage Ifla, those with involved nodes
are in Stage Illb. Stage Illb also includes
patients with T4 tumour, i.e. patients whose
tumour directly extends to skin or chest wall
(2/20 patients).
Stage 1: T,NoMo-Tumour of 2 cm or less;
negative axillary nodes; no metastases.
Stage Ila: T2NoMo-Tumour 2-5 cm; nega-
tive axillary nodes; no metastases.
Stage Ilb: TlNlMo-Tumour of 2 cm or less;A. HOGAN-RYAN ET AL.
positive mobile axillary nodes; no meta-
stases.
T2N1Mo-Tumour 2-5 cm; positive mobile
axillary nodes; no metastases.
Stage Illa: T3NoMo-Tumour >5 cm; nega-
tive axillary nodes; no metastases.
Stage Illb: T3N1Mo-Tumour >5 cm; posi-
tive mobile axillary nodes; no metastases.
T4anyNMo-Tumour of any size, with
direct extension to the chest wall; negative
or positive (mobile or fixed) homolateral
axillary or supraclavicular nodes; no
metastases.
T1T2T3, N2 or N3, Mo-Tumour of any
size; positive fixed axillary nodes (N2).
Homolateral supraclavicular or infra-
clavicular lymph nodes containing growth
or oedema ofthe arm (N3); no metastases.
Stage IV: Any T, any N, M1-Tumour ofany
size; positive or negative nodes; evidence
of distant metastases.
Metastatic disease was diagnosed clinically,
radiographically or isotopically.
Stage I Group consisted of 10 patients.
Stage II Group consisted of 13 patients
(7 Ila and 6 IIb).
Stage III Group consisted of 23 patients
(3 Illa and 20 Illb).
Stage IV Group consisted of 19 patients.
The sera were stored at -22°C within 2 h
of sampling, and assayed within 7 days.
Sialic acid was measured by the method of
Warren (1959) after hydrolysis with 0-iN
HCl at 800C for 1 h. Spectrophotometric read-
ings were determined both at 532 nm and
549 nm to allow for correction of interfering
2-deoxyribose (Warren, 1959). CEA was
measured using the kit supplied by CIS
(France). Free antigen CEA was separated
from antibody-antigen complex by a double-
antibody method. Serum alkaline phos-
phatase was measured by centrifugal analysis
using Smith Klein Spin Chem reagents
(paranitrophenyl phosphate-buffer system).
Total urinary hydroxyproline was measured
with the Hypronosticon kit supplied by
Organon.
RESULTS
Free sialic acid was not detected in the
sera of normal or breast-cancer patients.
The amount of bound sialic acid in
normal sera (1-65 + 0-27 mM) was similar
TABLE I.-Mean sialic acid values pre-
viously published for control sera, using
the method of Warren (1959) (thio-
barbituric acid)
Author
Saifer & Garstenfeld (1962)
McNeill et al. (1965)
Watkins et al. (1974)
Silver et al. (1978)
Ryan et al. (this paper)
Sialic acid
(mM)
1-78 + 0-23 (34)
1-69 + 0-18 (26)
1-69 + 0-19 (31)
1-50+0-40 (30)
1-65 + 0-27 (56)
to that in other published studies
using the thiobarbituric acid method of
Warren (Table I). Inter-assay mean and
standard deviation (s.d.) was 1-83+0-10
mM (n= 10) and intra-assay mean and
s.d. was 1-85+0-19 mm (n=10). The
mean sialic acid values (in mM) found in
the patients with breast cancer were as
follows:
Stage I
Stage Ila
Stage lIb
Stage Illa
Stage IIIb
Stage IV
E
1-76 + 0-23
1-75 + 0-38
2-0 +0-36
1-95 + 0-30
2-22 + 0-43
2-86 + 0-50
UONIKUL U I U IIA UIIB UIIIAUIIIBU IV
(56) (10) (13) (23) (19)
Fia. 1.- Serum sialic acid concentration in
control subjects and staged breast-cancer
patients. The broken line represents the
"cut-off point" of 2-1 mM.
I
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TABLE II.-Mean serurn sialic acid values (mM) previously published for unspecifted
solid tumours and breast cancer
Method and Autlhor
WVarren (1959):
Saifer & Garstenfeld (1962)
MIeNeill et.al. (1965)
WA'atkins et al. (1974)
Silver et (l. (1978)
(Melanoma)
Diphenylamine:
Winzler (1955)
Bra(dly et al. (1977)
Chromatography:
Macbeth & Bekesi (1962)
Mrochek et al. (1976)
* Lo. =Local. t Reg. =Regional.
Malignant tumour
C-A
Lo.* Reg.t Adv.j
2 2
(15)
2 3 2-5
(I1) (8)
Breast cancer
Lo.* Reg.t Adv.I
4-18
(1)
2-8
(34)
2-7
(14)
2-8
(6)
4-6(
(15)
2-8 3 2 3-96
(23) (28) (11)
3-5 2-9 3-45
(21) (15) (4)
Only 4/21 elevated
during treatment
$ Adv. =Advanced.
TABLE III. Naruber ofpatients with raised marker levels
Stage I
Stage II
Stage Ill
Stage IV
Sialic
aci(1
1/10
5/13
15/23
15/19
CEA
0/10
0/13
8/22
13/19
Alkaline
phos-
phatase
0/10
0/12
0/6
3/16
Hydroxy-
proline
0/10
3/13
4/19
8/19
ESR
0/10
2/10
8/16
10/15
Mean sialic acid values published for a
variety of solid tumours including breast
cancer are shown in Table II. Mean sialic
acid values in the sera of patients in this
series with metastatic disease were sig-
nificantly higher than control values
(P < 0 001). As a group, the patients with
localized disease (Stages I and II) had a
mean sialic acid value of 18 + 033 mM
which was not significantly different to
control values (P < 04 1), but patients with
locally advanced disease (Stage III) had a
mean serum sialic acid value significantly
higher than control (P < 0-001). However,
18/23 ofthis group had nodal involvement.
When these groups were subdivided,
mean sialic acid values in Stages Ilb and
IIlb (24/26 patients had nodal involve-
ment) were significantly higher than con-
trol values (P < 0.02 and P < 0-001 re-
spectively). These results show that sialic
acidlevel increases as lymph nodes become
involved and metastatic disease develops.
For the purpose ofthis paper, serum sialic
acid levels were considered raised when
the value was greater than 2 1 mm (96%
of control group had serum sialic acid
values <2 1 mM). When the number of
patients with raised serum sialic acid con-
centration is examined, the relationship to
tumour stage is apparent (Table III).
Serum sialic acid levels did not correlate
with serum CEA levels (r= 0.15).
Serum CEA levels were considered
raised at values greater than 10 ng/ml.
Mean CEA levels for 20 control donors
was 2-7 + 4-4 ng/ml. Inter-assay mean and
s.d. for 3 pooled sera were 5-5 + 1-6 (n = 28),
20-3+2-9 (n=28) and 110+18 (n=28).
Intra-assay mean and s.d. for 3 pooled
sera were 0 34+0-87 (n=59), 2*0+1-54
(n=23) and 1b64+1-82 (n=24). Raised
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FIG. 2.-Percentage of each group which had
elevated biochemical values.
CEA occurred in Stage III and IV patients
only. The percentage of each group with
raised sialic acid and CEA values is shown
in Fig. 2.
Using a cut-off level of 20 mm (ESR,
1h Westergren) in patients (all over 45
years) (Bottinger & Svendberg, 1967)
10/15 patients with distant metastases and
10/26 patients with localized disease had
high values. The 2 Stage II patients whose
ESR was raised had axillary node involve-
ment. Serum sialic acid levels did not
correlate with ESR, but, of the patients
with raised ESR 2/2 Stage II, 7/8 Stage
III and 10/10 Stage IV had raised sialic
acid levels.
Urinary hydroxyproline was measured
in 2h urine collections (Powles et al., 1976).
Mean hydroxyproline excretion in control
subjects was 29 + 8-6 mg/l (n= 25). Inter-
assay mean and s.d. was 47 + 11 3 (n= 10)
and intra-assay mean and s.d. was 44-2 +
164 (n = 9). Hydroxyproline values > 45
mg/l were considered raised.
Serum alkaline phosphatase was con-
sidered raised when > 95 i.u. in subjects
over 45 years (Biochemistry ]Department,
St Vincent's Hospital, unpublished re-
sults).
Table III shows a comparison of the
number ofabnormal values in Stages I-IV
of sialic acid, CEA, alkaline phosphatase,
hydroxyproline and ESR. Table IV shows
the relationship of these abnormal values
to sites of metastases. From these and
from Fig. 2, which shows the percentage
of each group with raised biochemical
levels, it can be seen that the best correla-
tion with staging is with sialic acid and
CEA, followed by ESR.
DISCUSSION
We wish to analyse these results in
terms of correlation with : (1) tumour
stages, (2) lymph-node involvement and
(3) other biochemical values (e.g. serum
CEA).
Serum sialic acid levels have previously
been measured in breast cancer by
Macbeth & Bekesi (1962) who found no
significant elevation in 36 patients with
localized disease, but 4/4 patients with
metastatic involvement had raised levels.
Mrochek et al. (1976) studied sera of un-
staged breast cancer during therapy, and
noted that only 4/21 had serum sialic acid
values greater than 2 x s.d. above the
control mean.
We have shown that serum sialic acid
concentrations were raised in breast cancer
and reflected tumour stage (Fig. 1). One
of 10 Stage I, 5 of 13 Stage II, 15 of 23
Stage III and 15 of 19 Stage IV had high
levels. Mean sialic acid values in the sera
of patients with metastatic disease were
significantly higher than in control sera.
TABLE IV.-Number ofpatients with distant metastases (Stage IV) who had raised marker
levels
Alkaline
phos- Hydroxy-
phatase proline
:3/12 6/13
0/2 2/2
0/2
0/1 (/1
0/1 0/1
Site of
metastases
Bone
Bone and luing
Lung
Lymph nodle
Skin
Sialic
acid
11/13
2/2
2/2
0/1
0/1
CEA
10/13
1/2
1/2
1/1
0/1
ESR
8/11
2/2
0/1
0/1
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As a group, the patients with localized
breast cancer (Stages I and II) had a mean
sialic acid value not significantly different
from the control mean. Patients with
advanced localized disease (Stage III) had
significantly raised mean sialic acid values,
but 87% of Stage III group had nodal
involvement.
The probable relationship to nodal
involvement is illustrated by the fact that
of 10 with Ila or Illa (negative nodes)
only 3 (300o) had high sialic acid levels,
whereas of 26 with Ilb and Illb disease
(positive nodes) 17 (65%) had high levels.
Mean sialic acid values in Stages Ilb and
IJIb were significantly higher than con-
trol. Of 2/11 Stage Ila patients with high
levels, one subsequently developed distant
metastases and in the other the level was
borderline (viz. 2-12 mM).
We found no significant correlation
between serum sialic acid levels and serum
CEA values (P < 0 5). This would indicate
that CEA and sialic acid measure different
parameters, e.g. CEA is an immunological
marker and sialic acid may reflect serum
sialoglycoprotein derived from sources
additional to tumour-cell surface.
A higher proportion of patients had
raised sialic acid levels compared to raised
serum CEA, in all stages of breast cancer,
especially the earlier stages. Serum sialic
acid was raised in 56% and serum CEA in
3300 of all breast-cancer patients. In
patients with distant metastases serum
sialic acid was raised in 790% compared to
raised CEA in 68%, whilst 17/19 (80%)
had either raised sialic acid or CEA.
Coombes et al. (1977) showed that with
development of metastases, the percent-
age of breast-cancer patients with high
CEA levels ( > 20 ng/ml) was 810% and
Tormey et al. (1977) reported that 76%
of breast cancer patients with metastases
had high (> 3 ng/ml) CEA values. These
figures are similar to our series in meta-
static disease (680 °).
Reviewing a number of markers (Fig. 2)
one can see that sialic acid seems to be
the most sensitive marker of advancing
disease, followed closely by CEA and ESR.
As levels of acute-phase proteins (in-
cluding acid glycoprotein) rise in response
to infection, inflammation, trauma and
injury, care must be taken in interpreting
sialic acid results. Raised serum sialic acid
was also reported in tuberculosis, rheuma-
toid arthritis and multiple sclerosis
(Macbeth & Bekesi, 1962) and raised
values were found in patients with renal
failure but not liver damage (Gray et al.,
1976). Whilst serum sialic acid levels are
not specific for malignancy, they may be
of adjunctive value in tumour-stage
assessment in association with other
markers.
In conclusion, serum sialic acid levels
correlate with advancing stage of breast
cancer, appear to be higher in patients
with lymph-node metastases, and may be
a more sensitive marker of advancing
disease than CEA, ESR, hydroxyproline
or alkaline phosphatase.
The authors wishi to thank Cherry Ryan for
measuring hydroxyproline, and Miss M. Doolin
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